Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors
Purpose
This study is an open-label, multicenter study for Continued Characterization of Safety and Tolerability of TT-00420 (tinengotinib) Tablet Monotherapy in Adult Patients with Advanced Solid Tumors
Conditions
- Advanced Solid Tumors
- Cholangiocarcinoma
Eligibility
- Eligible Ages
- All ages
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Subject is currently enrolled in a pre-defined TransThera-sponsored parent study and is receiving tinengotinib as a single agent. 2. Subject is currently deriving clinical benefit from the study treatment, as determined by the investigator.
Exclusion Criteria
- Subject has been permanently discontinued from tinengotinib in the parent protocol for any reason other than enrollment in the Rollover study 2. Subject does not meet the criteria specified in the parent protocol for continued treatment on study.
Study Design
- Phase
- Study Type
- Expanded Access
Recruiting Locations
University of Chicago Medical Center
Chicago, Illinois 60637
Chicago, Illinois 60637
Roswell Park Comprehensive Cancer Center
Buffalo, New York 14203
Buffalo, New York 14203
Sarah Cannon Research Institute
Nashville, Tennessee 37203
Nashville, Tennessee 37203
MD Anderson Cancer Center
Houston, Texas 77030
Houston, Texas 77030
UW Carbone Cancer Center
Madison, Wisconsin 53705
Madison, Wisconsin 53705
More Details
- Status
- Available
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Detailed Description
This is a Rollover study. Only subjects who continue to receive clinical benefit from continuation of tinengotinib monotherapy and are tolerating tinengotinib at the time of enrollment are eligible to participate on this study. Subjects on this rollover study may continue to receive tinengotinib at the dose that they were previously receiving on the TransThera parent study and may continue for as long as the subject continues to benefit from treatment.